GSK plc (BCBA:GSK)
Argentina · Delayed Price · Currency is ARS | Market Cap | 143.01T +69.5% |
| Revenue (ttm) | 59.80T +4.0% |
| Net Income | 10.63T +84.9% |
| EPS | 2,590.57 +86.6% |
| Shares Out | n/a |
| PE Ratio | 13.45 |
| Forward PE | 10.22 |
| Dividend | 586.75 (3.08%) |
| Ex-Dividend Date | May 15, 2026 |
| Volume | 5 |
| Average Volume | 488 |
| Open | 18,990 |
| Previous Close | 19,050 |
| Day's Range | 18,990 - 19,110 |
| 52-Week Range | 11,125 - 22,760 |
| Beta | n/a |
| RSI | 44.63 |
| Earnings Date | Apr 29, 2026 |
About GSK plc
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer. It a... [Read more]
Financial Performance
In 2025, GSK plc's revenue was 32.67 billion, an increase of 4.11% compared to the previous year's 31.38 billion. Earnings were 5.72 billion, an increase of 121.98%.
Financial numbers in GBP Financial StatementsNews
GSK announces Japan’s MHLW expanded eligible population for Arexvy
GSK (GSK) announced that Japan’s Ministry of Health, Labour and Welfare, MHLW, has expanded the eligible population for Arexvy, to include adults aged 18 to 49 years at increased risk…
GSK enters into exclusive strategic collaboration with Sino Biopharm
GSK (GSK) announced that it has entered into an exclusive strategic collaboration with Sino Biopharmaceutical (SBMFF), through its subsidiary Chia Tai Tianqing Pharmaceutical Group, or CTTQ, to accele...
GSK to team up with Sino Biopharma for China launch of hepatitis B treatment
GSK on Monday said it had entered into a strategic collaboration with Hong Kong-listed Sino Biopharmaceutical to accelerate the launch of its hepatitis B treatment bepirovirsen in mai...
Halozyme announces global collaboration and license agreement with GSK
Halozyme Therapeutics (HALO) announced the company entered into a global collaboration and license agreement with GSK (GSK). Under the collaboration, GSK has licensed Halozyme’s ENHANZE drug delivery ...
GSK partners with Julie Bowen, Ty Burrell to raise meningitis awareness
GSK (GSK) announced new campaign spokespeople, Julie Bowen and Ty Burrell, as part of its Ask2BSure public health campaign to raise awareness and encourage parents to “ask to be sure”…
Julie Bowen and Ty Burrell team up with GSK to raise awareness about meningitis risks for teens and young adults
PHILADELPHIA--(BUSINESS WIRE)-- #Adolescents--Julie Bowen and Ty Burrell team up with GSK to raise awareness about meningitis risks for teens and young adults.
GSK price target lowered to 2,100 GBp from 2,250 GBp at Citi
Citi lowered the firm’s price target on GSK (GSK) to 2,100 GBp from 2,250 GBp and keeps a Neutral rating on the shares.
The Most Important Part of These 3 Big Pharma Earnings Reports Wasn't the Beat
Earnings season is in full swing, and on April 29, three Big Pharma mainstays reported Q1 2026 earnings. Investors were looking for strong results—and strong guidance—that could serve as a sorely need...
GSK plc Earnings Call Transcript: Q1 2026
Q1 2026 saw 5% sales growth to £7.6B, led by Specialty Medicines and Shingrix, with core operating profit up 10% and EPS up 9%. The company confirmed full-year guidance, advanced its pipeline, and executed key acquisitions, while maintaining strong cash generation and disciplined capital allocation.
GSK plc Quarterly report: Q1 2026
GSK plc has published its Q1 2026 quarterly earnings report on April 29, 2026.
GSK plc Slides: Q1 2026
GSK plc has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on April 29, 2026.
GSK plc Earnings Call Transcript: Q1 2026
Q1 2026 saw 5% sales growth to £7.6B, led by Specialty Medicines and Shingrix, with core operating profit up 10% and EPS up 9%. The company confirmed full-year guidance, advanced its pipeline, and executed key acquisitions, while maintaining strong cash generation and disciplined capital allocation.
GSK plc Quarterly report: Q1 2026
GSK plc has published its Q1 2026 quarterly earnings report on April 29, 2026.
GSK plc Slides: Q1 2026
GSK plc has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on April 29, 2026.
UK's biggest drugmakers see surprise profit bump, even as pharma grapples with U.S. policies
Britain's largest drugmakers saw 2026 get off on a positive note, with AstraZeneca and GSK both reporting core earnings ahead of expectations on Wednesday The CEOs of a number of European pharma giant...
GSK Earnings Boosted by Higher Specialty Medicine Sales
The pharmaceutical giant said core operating profit for the first quarter was £2.65 billion compared with £2.53 billion for the same period a year earlier.
GSK beats quarterly profit estimates on strength in respiratory, general medicines
British drugmaker GSK reported first-quarter profit above analysts' expectations on Wednesday, helped by strong sales of its respiratory and other general medicines.
Top FTSE 100 shares to watch next week: Lloyds, Barclays, GSK, Natwest
The FTSE 100 Index pulled back this week as the US-Iran war continued and after the UK published a hot consumer inflation report. It dropped to £10,365 from this month's high of £10,687.
FTSE 100 Index retreats ahead of Lloyds, Barclays, Natwest, GSK earnings
The FTSE 100 Index pulled back for three consecutive days as companies exposed to the ongoing US-Iran war slipped and as the UK published a strong inflation report. It also dropped as market particip...
GSK sees blockbuster potential in targeted cancer therapy after promising early data
British drugmaker GSK's experimental targeted cancer drug Mo-rez has blockbuster potential, its head of oncology research has told reporters, after early data showed the drug helped shrink tumors in ...
GSK withdrew an application of a drug touted by Trump and RFK Jr. as a potential treatment for autism. The drug's label last month was updated so that generic versions of it can be marketed for a rare genetic, neurological condition, but not autism.
Generic versions of the drug will still be available to treat a rare genetic condition.
Samsung Biologics completes acquisition of GSK's manufacturing facility in Rockville, Maryland
Adds 60,000 liters of drug substance capacity, bringing the total to 845,000 liters Marks Samsung Biologics' geographical diversification and establishes its first U.S. manufacturing presence, expandi...
GSK plc Transcript: Goldman Sachs 9th Annual Biopharma Innovation Summit
Major clinical milestones are expected this year for camlipixant in chronic cough and bepirovirsen in hepatitis B, both targeting significant unmet needs. The R&D strategy emphasizes validated mechanisms, differentiation, and AI-driven innovation, with a broad pipeline in respiratory and specialty medicine.